These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 17549294

  • 1. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
    Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG.
    Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators.
    N Engl J Med; 2008 Jun 26; 358(26):2776-86. PubMed ID: 18579812
    [Abstract] [Full Text] [Related]

  • 5. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators.
    Lancet; 2008 Jul 05; 372(9632):31-9. PubMed ID: 18582928
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST.
    Am J Cardiovasc Drugs; 2012 Feb 01; 12(1):57-72. PubMed ID: 22272729
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
    Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.
    Pharmacoeconomics; 2012 Feb 01; 30(2):87-101. PubMed ID: 22187932
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA, Espada NG, Merino RG, González TC.
    Thromb Res; 2012 Aug 01; 130(2):183-91. PubMed ID: 22425218
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
    Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators.
    J Thromb Haemost; 2006 Jan 01; 4(1):121-8. PubMed ID: 16409461
    [Abstract] [Full Text] [Related]

  • 18. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB, Zhang JD, Shen H, Jiang YY.
    Eur J Clin Pharmacol; 2010 Nov 01; 66(11):1099-108. PubMed ID: 20812009
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G, Zhang R, Wu X, Wang D, Ying K.
    Thromb Res; 2015 May 01; 135(5):816-22. PubMed ID: 25728496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.